$2.13
-0.03 (-1.39%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where GRCE is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional
Held by 4 tracked-famous managers (CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 5.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAHNCT05995405Incidence (% or proportion) of subjects with at least one episode of clinically significant hypotension with a reasonable possibility that GTX-104/oral nimodipine caused the event, according to the Endpoint Adjudication Committee.Randomized · Open-label · Treatment | Phase 3 | Active, not recruiting | Drug: GTX-104, Nimotop 30 MG Oral Capsule | Aneurysmal Subarachnoid Hemorrhage (aSAH) | 100 | Dec 2024 | 2024-10-01 |
| Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy SubjectsNCT05531890AUC from 0 to 72 hours post-doseRandomized · Open-label · Other | Phase 1 | Unknown status | Drug: GTX-102 medium dose fast Period 1 and Period 2, GTX-102 medium dose slow Period 1 and Period 2, GTX-102 high dose fast Period 1 and Period 2, GTX-102 low dose fast Period 1 and Period 2, Betamethasone solution as intramuscular injection Period 1 and Period 2, Betamethasone Oral Solution Period 1 and Period 2 | Ataxia Telangiectasia | 48 | 2022-11-24actual | 2023-01-23 |
| Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy SubjectsNCT05517486Cmax between 0 hour to 240 hour after study drug administrationRandomized · Open-label · Treatment | Phase 1 | Unknown status | Drug: GTX-101, Bupivacaine HCl subcutaneous injection | Postherpetic Neuralgia | 48 | 2022-08-21actual | 2023-01-23 |
| Relative Bioavailability of Intravenous GTX-104 Compared to Oral Nimodipine Capsules in Healthy SubjectsNCT05418348Cmax Day 1Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: GTX-104, Nimodipine Capsules | Aneurysmal Subarachnoid Hemorrhage | 58 | 2022-02-17actual | 2023-08-31 |
| A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)NCT03361501Percent change in fasting TG levels from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in patients with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L).Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: CaPre, Placebo | Hypertriglyceridemia | 278 | 2019-09-24actual | 2020-08-12 |
| A Phase 3 STudy of CaPRe In LOwering Very hiGh TriglYcerides (TRILOGY 1)NCT03398005Percent change in fasting TG levels from baseline (average of Week -2, -1, and 0) to Week 12 (average of Week 11 and 12) in patients with fasting TG levels ≥500 mg/dL and ≤1500 mg/dL (≥5.7 mmol/L and ≤17.0 mmol/L).Randomized · Double-masked · Treatment | Phase 3 | Completed | Drug: CaPre, Placebo | Hypertriglyceridemia | 256 | 2019-07-21actual | 2020-01-18 |
| TRIal For Efficacy of Capre on hyperTriglyceridemiANCT01455844Percent (%) change in triglycerides between the baseline and the 12-week assessment visit.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: CaPre (TM), CaPre (TM) · Other: Placebo | Hypertriglyceridemia | 387 | Jun 2014actual | 2014-08-22 |
| Assess the Safety and Efficacy of NKPL66 (CaPre™) in the Treatment of Mild-to-high HypertriglyceridemiaNCT01516151Percent change in fasting blood circulating serum TGsRandomized · Open-label · Treatment | Phase 2 | Completed | Dietary supplement: CaPre™, CaPre™, CaPre™, CaPre™ · Drug: Lipid Lowering Medication | Hypertriglyceridemia | 289 | May 2013actual | 2014-01-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19